OncoMatch/Clinical Trials/NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Is NCT06577987 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CID-078 Monotherapy for advanced solid tumor.
Treatment: CID-078 Monotherapy — This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Neuroendocrine Tumor
Biomarker criteria
Required: RB1 genomic alteration
solid tumors harboring a RB1 genomic alteration
Required: RB1 protein loss of function
solid tumors harboring...Rb protein LoF
Required: CDKN2A genomic alteration
solid tumors harboring a...CDKN2A...genomic alteration
Required: CDKN2B genomic alteration
solid tumors harboring a...CDKN2B genomic alteration
Disease stage
Metastatic disease required
measurable disease per RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: all available therapies
has progressed or was non responsive to available therapies and for which no standard or available curative therapy exists
Cannot have received: CID-078 (CID-078)
Prior therapy with CID-078
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL (last transfusion > 14 days prior); Platelets ≥ 100 × 10^9 cells/L (last platelet transfusion > 14 days prior); ANC ≥ 1.2 × 10^9 cells/L (last dose of hematopoietic growth factors > 14 days prior)
Kidney function
CrCl ≥ 60 mL/min/1.73 m2 or eGFR ≥ 60 mL/min/1.73 m2; for patients < 18 years: serum creatinine within normal limits or eGFR ≥ 60 mL/min/1.73 m2
Liver function
Total bilirubin ≤ 1.5 × ULN unless prior history of Gilbert's syndrome with Sponsor Medical Monitor approval; AST/ALT ≤ 2.5 × ULN, or ≤ 5 × ULN if due to liver involvement by tumor
Cardiac function
QTc interval (Fridericia) ≤ 470 msec
See inclusion criteria 8 and exclusion criteria 8
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- START Midwest · Grand Rapids, Michigan
- Comprehensive Cancer Centers of Nevada · Las Vegas, Nevada
- UH Seidman Cancer Center · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06577987 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CID-078 disqualifies patients from enrollment.
Does this trial require RB1?
Yes, RB1 genomic alteration is a required biomarker for enrollment.
Does this trial require RB1?
Yes, RB1 protein loss of function is a required biomarker for enrollment.
Does this trial require CDKN2A?
Yes, CDKN2A genomic alteration is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify